MDT

86.1

0%↓

113.79

+1.57%↑

VEEV

175.57

-0.19%↓

HQY

83.25

+2.61%↑

CSBR

5.69

-0.18%↓

MDT

86.1

0%↓

113.79

+1.57%↑

VEEV

175.57

-0.19%↓

HQY

83.25

+2.61%↑

CSBR

5.69

-0.18%↓

MDT

86.1

0%↓

113.79

+1.57%↑

VEEV

175.57

-0.19%↓

HQY

83.25

+2.61%↑

CSBR

5.69

-0.18%↓

MDT

86.1

0%↓

113.79

+1.57%↑

VEEV

175.57

-0.19%↓

HQY

83.25

+2.61%↑

CSBR

5.69

-0.18%↓

MDT

86.1

0%↓

113.79

+1.57%↑

VEEV

175.57

-0.19%↓

HQY

83.25

+2.61%↑

CSBR

5.69

-0.18%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.21 9.01

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.11

Max

1.23

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+92.31% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-40M 134M
Eelmine avamishind	-7.8
Eelmine sulgemishind	1.21

Uudiste sentiment

By Acuity

13%

87%

23 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. märts 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30. märts 2026, 22:36 UTC

Uudisväärsed sündmused

Australian Government Rules Out Boots on the Ground in the Middle East

30. märts 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30. märts 2026, 21:00 UTC

Tulu

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30. märts 2026, 20:15 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30. märts 2026, 23:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 23:40 UTC

Market Talk

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30. märts 2026, 23:36 UTC

Market Talk

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30. märts 2026, 23:12 UTC

Market Talk

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30. märts 2026, 22:49 UTC

Market Talk

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30. märts 2026, 22:44 UTC

Market Talk

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30. märts 2026, 22:43 UTC

Market Talk

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30. märts 2026, 22:42 UTC

Market Talk

South32 Should Go for Growth, Says New Bull -- Market Talk

30. märts 2026, 22:18 UTC

Market Talk

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30. märts 2026, 22:05 UTC

Market Talk

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30. märts 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350M

30. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30. märts 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30. märts 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30. märts 2026, 21:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 21:25 UTC

Market Talk

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30. märts 2026, 21:03 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. märts 2026, 20:09 UTC

Tulu

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30. märts 2026, 20:00 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

92.31% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 92.31%

Kõrge 2.5 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

23 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.